The original disclosure in Japanese was released on January 30, 2015 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2014
FY2015 (April 1, 2014 - March 31, 2015) [UNAUDITED]

Company name:	Takara Holdings Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	2531
URL:	http://www.takara.co.jp/
Company representative:	Toshio Kakimoto, President
Contact:	Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
	TEL : (075)241-5124

Quarterly statement filing date (as planned): February 6, 2015

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2014 (April 1, 2014 – December 31, 2014)

(1) Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2014		Nine months ended December 31, 2013	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	166,054	4.1	159,519	2.9
Operating income	10,580	19.0	8,891	(2.9)
Ordinary income	10,969	19.2	9,205	(0.4)
Net income	5,984	(43.0)	10,503	117.6
Net income per share (Yen)	29.74		51.86	
Fully diluted net income per share (Yen)	-		51.85	
Note: Comprehensive income	8,932	(61.5)	23,207	324.5

(2) Financial position

	As of December 31, 2014	As of March 31, 2014
	(Millions of yen)	(Millions of yen)
Total assets	246,063	238,577
Net assets	153,531	146,422
Equity ratio (%)	48.6	50.9
(Reference) Equity	128,230	121,431

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2014	Year ending March 31, 2015	Year ending March 31, 2015 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	11.00		9.00
Annual	11.00		9.00

Notes: Correction of dividend forecast from the most recent dividend forecast : No
The annual dividend for the year ended March 31, 2014 comprises an ordinary dividend of ¥9.00 and a special dividend of ¥2.00.

3. Forecast for the year ending March 31, 2015 (April 1, 2014 – March 31, 2015)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2015	
	(Millions of yen)	(%)
Net sales	218,000	4.0
Operating income	9,800	3.3
Ordinary income	10,000	0.9
Net income	5,300	(48.4)

Net income per share (Yen)	26.34

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in specific subsidiaries) : No

(2) Applying of specific accounting treatments of the quarterly consolidated financial statements : No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : Yes
3) Changes in accounting estimates : Yes
4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of December 31, 2014 : 217,699,743
As of March 31, 2014 : 217,699,743

2) Number of treasury stocks at year end

As of December 31, 2014 : 16,473,608
As of March 31, 2014 : 16,466,424

3) Average number of outstanding shares

Nine months ended December 31, 2014 : 201,228,103
Nine months ended December 31, 2013 : 202,553,399

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2014 ---------- 2
(1) Consolidated Financial Results ---------- 2
(2) Consolidated Financial Position ---------- 4
(3) Qualitative Information Regarding Consolidated Forecasts ---------- 4
2 Summary Information (Notes) ---------- 4
Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
3. Consolidated Quarterly Financial Statements ---------- 5
(1) Consolidated Quarterly Balance Sheets ---------- 5
(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 7
Consolidated Quarterly Statements of Income
(For the Nine Months Ended December 31, 2014 and 2013) ---------- 7
Consolidated Quarterly Statements of Comprehensive Income
(For the Nine Months Ended December 31, 2014 and 2013) ---------- 8
(3) Notes on Consolidated Quarterly Financial Statements ---------- 9
(Notes on Premise of Going Concern) ---------- 9
(Notes on Material Changes in Shareholders' Equity) ---------- 9
(Segment Information) ---------- 9

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2014

(1) Consolidated Financial Results

In the nine months ended December 31, 2014, the Japanese economy experienced anticipation of an improvement in corporate performance, primarily among exporters, as a result of the sharp depreciation in the value of the yen following additional monetary easing by the Bank of Japan. However, there were concerns about the impact of rising prices for imported raw materials on earnings at domestic demand-oriented companies. Furthermore, recovery in private consumption was patchy due in part to the rise in the price of food and other goods because of the depreciation in the value of the yen in addition to the slump in private consumption following the increase in the rate of the consumption tax. Meanwhile, the uncertainty outside Japan persisted as economic growth in Europe and emerging countries clouded over slightly while the economy in the United States remained firm.

In this environment, we endeavored to further improve corporate value in accordance with the three-year Takara Group Medium-Term Management Plan FY2017 under which our basic policy is that "To achieve the Takara Group Vision 2020 (our long-term vision), we will improve domestic business profitability and expand our overseas business, while at the same time building a well-balanced business structure that can hold up well to business environment changes by accelerating the growth of our Biomedical business."

In the domestic alcoholic beverages business, the Group focused its resources on developing original new products and cultivating brands in response to diversifying customer preferences. In the seasonings and raw alcohol business, the Group made concerted efforts to increase sales by proposing differentiated products that meet customer needs.

In the overseas alcoholic beverages business and Japanese food wholesales business in overseas markets, the Group worked to accelerate business expansion by spreading Japanese food culture across the globe.

In the Biomedical business, management resources were focused on three areas – the Bioindustry business, the Gene Therapy business, and the AgriBio business – in pursuit of improved performance.

As a result, in the nine months ended December 31, 2014, net sales were up 4.1% year on year to ¥166,054 million due to the inclusion of sales from subsidiaries that were newly consolidated during the previous fiscal year and an increase in sales at overseas subsidiaries due to the depreciation in the value of the yen among other factors. Gross profit also rose 5.8% year on year to ¥65,078 million in tandem with the increase in net sales.

Selling, general and administrative (SG&A) expenses were up 3.6% year on year to ¥54,497 million, successfully held down relative to the increase in gross profit, as personnel and other expenses outside Japan rose due to the new consolidation of subsidiaries and the depreciation in the value of the yen. Consequently, operating income rose 19.0% year on year to ¥10,580 million. In non-operating income and expenses, there were increases in dividends income and share of profit of entities accounted for using equity method. Thus, ordinary income also rose 19.2% year on year to ¥10,969 million.

In regard to extraordinary income and loss, extraordinary income fell considerably year on year as the ¥9,261 million gain on sales of stocks of subsidiaries and affiliates due to the sale of a portion of the stock held in Takara Bio Inc. recorded in the corresponding period of the previous fiscal year was not recorded in the period under review. As a result, income before income taxes and minority interests declined by 41.6% year on year to ¥10,752 million, and net income also dropped considerably by 43.0% to ¥5,984 million.

Results by business segment were as follows.

[Takara Shuzo Group]

In the nine months ended December 31, 2014, net sales increased 3.8% year on year to ¥146,178 million as a result of an increase in yen-translated sales at overseas subsidiaries due to the depreciation in the value of the yen in addition to sales at COMINPORT DISTORIBUCIÓN S.L., which was newly consolidated, and TAZAKI FOODS LTD., which has become a consolidated subsidiary since the corresponding period of the previous fiscal year.

By product, sales of shochu products, particularly *ko*-type shochu, declined considerably. On the other hand, sales of sake increased due to considerable sales growth for the sparkling sake, *Sho-Chiku-Bai Shirakabe-gura Mio* for which sales channels expanded in September 2013. Furthermore, while sales of *Takara Shochu High Ball* remained robust, sales of light-alcohol refreshers declined due to a considerable fall in sales of *Takara Can Chu-Hi Jika-Shibori*. However, sales of other alcoholic beverages increased as wine and whisky continued to sell well. The decline in shochu sales weighed heavily, and overall sales of alcoholic beverages declined as a result.

Aside from this, sales of products such as seasonings and raw alcohol rose slightly while sales in transportation declined. In addition, sales in the Japanese food wholesale business in overseas markets, which included the new consolidated subsidiaries mentioned above, rose considerably affected by the depreciation in the value of the yen and contributed to the overall increase in sales in the segment.

Cost of sales was up 2.9% year on year to ¥91,977 million. This was thanks to a decline in the cost of sales ratio due to changes in the product mix at Takara Shuzo Co., Ltd. and an improvement in the cost of sales ratio in the Japanese food wholesale business in overseas markets despite increases in the cost of raw materials due to the depreciation in the

value of the yen. As a result, gross profit was also up 5.4% to ¥54,200 million. SG&A expenses were up 3.1% year on year to ¥45,764 million because of increases in transportation, personnel, management and other expenses resulting from new consolidation of subsidiaries. Accordingly, the Takara Shuzo Group recorded operating income up 19.8% year on year to ¥8,435 million for the nine months ended December 31, 2014.

[Takara Bio Group]

Net sales increased 7.0% year on year to ¥17,293 million. While the Bioindustry business saw sales of mainstay research reagents increase considerably, due in part to the impact of the depreciation in the value of the yen, with sales of scientific instruments also rising, sales of contracted research services fell. In the AgriBio business, sales of health foods and mushroom products both increased.

Cost of sales was up 4.5% year on year to ¥7,839 million. Consequently, gross profit increased 9.1% to ¥9,453 million. Although advertising and promotion expenses declined, an increase in personnel and research and development expenses led to a year-on-year increase of 5.6% in SG&A expenses to ¥8,190 million. Consequently, the Takara Bio Group recorded operating income up 39.1% to ¥1,263 million compared with the nine months ended December 31, 2013.

[Takara Healthcare]

Net sales for the nine months ended December 31, 2014 increased by 19.8% year on year to ¥1,230 million due to strong sales of the mainstay fucoidan-related products and isosamidin-related products in addition to sales growth for OEM cosmetics. The cost of sales ratio increased slightly due to the sales growth of OEM products, which have a high cost of sales ratio, but gross profit also rose, offsetting the increase in SG&A expenses resulting from the increase in advertising expenses. Takara Healthcare recorded operating income up 489.3% to ¥30 million compared with the nine months ended December 31, 2013.

[Other]

Net sales of business segments other than the reported segments decreased 2.3% year on year to ¥5,412 million, and operating income was down 48.1% to ¥104 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2013, to December 31, 2013)	Period under Review (from April 1, 2014, to December 31, 2014)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	51,992	49,675	95.5
Sake	18,767	19,817	105.6
Light-alcohol refreshers	21,228	20,249	95.4
Other alcoholic beverages	9,299	10,128	108.9
Alcoholic beverages total	101,288	99,870	98.6
Hon Mirin	11,655	11,368	97.5
Other seasonings	6,658	6,969	104.7
Seasonings total	18,314	18,338	100.1
Raw alcohol, etc.	5,065	5,378	106.2
Transportation	8,937	8,671	97.0
Japanese food wholesales business in overseas markets	6,039	12,747	211.1
Other	1,205	1,171	97.1
Total	140,850	146,178	103.8
Takara Bio Group	16,167	17,293	107.0
Takara Healthcare	1,027	1,230	119.8
Other	5,541	5,412	97.7
Sales not allocated to business segments and intersegment transactions	(4,067)	(4,060)	-
Total	**159,519**	**166,054**	**104.1**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥264,063 million as of December 31, 2014, up ¥25,486 million from March 31, 2014, the end of the previous fiscal year. This was due to a ¥19,485 million increase in current assets from the end of the previous fiscal year to ¥170,037 million resulting from factors including an increase in notes and accounts receivable-trade because of the annual year-end peak season and an increase in securities for the management of surplus funds despite a decrease in cash and deposits. Noncurrent assets increased by ¥6,000 million to ¥94,025 million due to such factors as an increase in property, plant and equipment due to capital expenditure and increase in investment securities due to a rise in the market prices of listed stocks and other items.

Total liabilities amounted to ¥110,532 million as of December 31, 2014, up ¥18,377 million from March 31, 2014. The main changes were an increase in long-term loans payable, an increase in accrued alcohol tax, and a decrease in income taxes payable.

Net assets stood at ¥153,531 million as of December 31, 2014, up ¥7,108 million from March 31, 2014 due to an increase in valuation difference on available-for-sale securities in addition to an increase in retained earnings.

(3) Qualitative Information Regarding Consolidated Forecasts

With regard to the Company's consolidated performance, the overseas business has remained robust, due in part to the impact of the depreciation in the value of the yen. As a result, as of December 31, 2014, net sales were largely in line with initial forecasts while operating income, ordinary income, and net income were outperforming initial forecasts. In the event that the Company deems it necessary to revise the full-year forecasts in line with future performance trends, the impact of changes in the expected rate of income taxes, and other factors, such revisions will be disclosed promptly.

Takara Bio Inc. (Securities Code: 4974, Tokyo Stock Exchange Mothers), a consolidated subsidiary, revised its full-year consolidated forecasts in Notice of Revision of Business Results Forecasts, Recording of Extraordinary Loss, and Reversal of Deferred Tax Assets released on January 30, 2015. See the press release for details.

2. Summary Information (Notes)

Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Accounting Standard for Retirement Benefits)

The Company adopted the provisions in the main text of paragraph 35 of the Accounting Standard for Retirement Benefits (Accounting Standards Board of Japan ("ASBJ") Statement No. 26, May 17, 2012) and the main text of paragraph 67 of the Application Guidance on Accounting Standard for Retirement Benefits (ASBJ Guidance No. 25, May 17, 2012) from the first quarter of this fiscal year, revising the method of calculating retirement benefit obligations and service expenses, modifying the method of attributing expected benefit to periods from the straight-line basis to the benefit formula basis as well as changing the discount rate from one based on the average remaining service years of its employees to a single weighted average discount rate reflecting the expected timing and amount of benefit payments.

In accordance with the transitional measures provided for in paragraph 37 of the Accounting Standard for Retirement Benefits for the application of the Accounting Standard for Retirement Benefits and its Guidance, the effect of the change in the method of calculation of retirement benefit obligations and service costs has been added to or deducted from retained earnings as of the beginning of the nine months ended December 31, 2014.

As a result, at the beginning of the nine months ended December 31, 2014, net defined benefit liabilities fell ¥313 million while other in investments and other assets increased by ¥359 million, retained earnings increased by ¥414 million and minority interests increased by ¥16 million. The impact on consolidated operating income, ordinary income and net income before taxes in the nine months ended December 31, 2014 was immaterial.

(Change in Accounting Policy that is Difficult to Distinguish from Change in Accounting Estimates)

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

Takara Bio reconsidered its method of depreciation and determined that this change from declining balance to straight-line depreciation is reasonable in view of the fact that the stable utilization of property, plant and equipment in research and development and production activities is anticipated because it has been 12 years since the company was established and facilities that include the Center for Gene and Cell Processing will be in operation from this fiscal year.

The impact of this change on consolidated operating income, ordinary income and net income before taxes in the nine months ended December 31, 2014 is an increase of ¥234 million respectively.

3. Consolidated Quarterly Financial Statements
(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2014	As of Dec. 31, 2014
Assets		
Current assets		
Cash and deposits	41,015	34,101
Notes and accounts receivable-trade	51,901	67,735
Securities	21,534	30,288
Merchandise and finished goods	26,729	27,780
Work in process	908	1,317
Raw materials and supplies	3,351	3,425
Other	5,254	5,536
Allowance for doubtful accounts	△143	△148
Total current assets	150,551	170,037
Noncurrent assets		
Property, plant and equipment	47,976	51,260
Intangible assets		
Goodwill	7,539	7,399
Other	4,123	4,096
Total intangible assets	11,662	11,496
Investments and other assets		
Investment securities	23,532	26,045
Other	5,077	5,417
Allowance for doubtful accounts	△223	△193
Total investments and other assets	28,386	31,269
Total noncurrent assets	88,025	94,025
Total assets	238,577	264,063
Liabilities		
Current liabilities		
Notes and accounts payable-trade	14,416	16,446
Short-term loans payable	5,914	5,616
Current portion of bonds	―	5,000
Accrued alcohol tax	8,376	12,826
Accrued expenses	4,480	5,772
Income taxes payable	5,621	2,234
Provision for sales promotion expenses	1,795	2,035
Other provision	2,103	1,308
Other	5,953	9,895
Total current liabilities	48,663	61,136
Noncurrent liabilities		
Bonds payable	25,000	20,000
Long-term loans payable	310	10,371
Net defined benefit liability	6,943	6,757
Long-term deposits received	5,591	5,644
Other	5,644	6,622
Total noncurrent liabilities	43,491	49,395
Total liabilities	92,154	110,532

(Millions of Yen)

	As of Mar. 31, 2014	As of Dec. 31, 2014
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,196	3,196
Securities	104,739	108,925
Merchandise and finished goods	∆9,931	∆9,937
Total noncurrent assets	111,230	115,410
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,941	7,544
Deferred gains or losses on hedges	279	709
Foreign currency translation adjustment	2,894	3,617
Remeasurements of defined benefit plans	1,085	947
Total accumulated other comprehensive income	10,200	12,819
Minority interests	24,991	25,300
Total net assets	146,422	153,531
Total liabilities and net assets	238,577	264,063

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Stetements of Comprehensive Income

(Consolidated Quarterly Statements of Income)

(For the Nine Months Ended December 31, 2014 and 2013)

(Millions of Yen)

	FY2014 3Q (Apr. 1, 2013 – Dec. 31, 2013)	FY2015 3Q (Apr. 1, 2014 – Dec. 31, 2014)
Net sales	159,519	166,054
Cost of sales	98,027	100,975
Gross profit	61,491	65,078
Selling, general and administrative expenses	52,599	54,497
Operating income	8,891	10,580
Non-operating income		
Dividends income	357	414
Other	445	542
Total non-operating income	802	957
Non-operating expenses		
Interest expenses	340	347
Other	147	220
Total non-operating expenses	488	568
Ordinary income	9,205	10,969
Extraordinary income		
Gain on sales of noncurrent assets	13	62
Gain on sales of investment securities	0	249
Gain on sales of subsidiaries and affiliates' stocks	9,261	―
Other	179	―
Total extraordinary income	9,453	312
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	103	226
Impairment loss	―	247
Loss on transfer of land	121	―
Other	36	55
Total extraordinary losses	262	529
Income before income taxes and minority interests	18,397	10,752
Income taxes-current	7,151	3,578
Income taxes-deferred	422	1,009
Total income taxes	7,574	4,588
Income before minority interests	10,823	6,163
Minority interests in income	319	179
Net income	10,503	5,984

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Nine Months Ended December 31, 2014 and 2013)

(Millions of Yen)

	FY2014_3Q (Apr. 1, 2013 - Dec. 31, 2013)	FY2015_3Q (Apr. 1, 2014 - Dec. 31, 2014)
Income before minority interests	10,823	6,163
Other comprehensive income		
Valuation difference on available-for-sale securities	2,489	1,602
Deferred gains or losses on hedges	387	426
Foreign currency translation adjustment	3,429	776
Remeasurements of defined benefit plans	—	△138
Share of other comprehensive income of associates accounted for using equity metho	230	101
Gain or loss on change in equity	5,847	—
Total other comprehensive income	12,384	2,768
Comprehensive income	23,207	8,932
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	22,164	8,602
Comprehensive income attributable to minority interests	1,042	329

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2013, to December 31, 2013)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	140,593	15,711	1,025	157,330	1,866	159,196	322	159,519
Intersegment	257	455	1	714	3,674	4,389	(4,389)	-
Total	140,850	16,167	1,027	158,045	5,541	163,586	(4,067)	159,519
Segment income (loss)	7,041	908	5	7,955	201	8,156	734	8,891

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥58 million and income of the Company not allocated to business segments of ¥675 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No significant items requiring inclusion.

II. Period under Review (From April 1, 2014, to December 31, 2014)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	145,928	16,708	1,228	163,864	1,848	165,712	341	166,054
Intersegment	250	585	1	836	3,564	4,401	(4,401)	-
Total	146,178	17,293	1,230	164,701	5,412	170,114	(4,060)	166,054
Segment income	8,435	1,263	30	9,729	104	9,833	746	10,580

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥46 million and income of the Company not allocated to business segments of ¥700 million.
3. Segment income has been adjusted to the operating loss of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

With this change, segment income for the Takara Bio Group for the nine months ended December 31, 2014 increased ¥234 million compared with the previous method of depreciation.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

An impairment loss of ¥247 million was recorded because the book value of idle assets at Takara Bio Group was reduced to the recoverable amount.

平成27年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2014

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
Takara Shuzo Group

要約損益計算書
Statements of Income (Summary)

3. タカラバイオグループ
Takara Bio Group

要約損益計算書
Statements of Income (Summary)

4. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)　→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成26年3月期 第3四半期累計	平成27年3月期 第3四半期累計 Apr. 1, 2014 - Dec. 31, 2014			平成26年3月期 通期	平成27年3月期 通期 Apr. 1, 2014 - Mar. 31, 2015		
	実績(a) FY2014(1Q-3Q) Actual (a)	実績(b) FY2015(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2014 Actual (c)	11/5予想(d) FY2015 Forecast announced Nov. 2014 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
宝酒造 グループ Takara Shuzo Group	140,850	146,178	5,327	103.8%	182,306	189,300	6,993	103.8%
タカラバイオ グループ Takara Bio Group	16,167	17,293	1,126	107.0%	23,905	＊ 25,200	1,294	105.4%
宝ヘルスケア Takara Healthcare Inc.	1,027	1,230	203	119.8%	1,424	1,600	175	112.3%
その他 Other, net	1,473	1,352	△ 121	91.8%	1,931	1,900	△ 31	98.4%
売上高 Net sales	159,519	166,054	6,535	104.1%	209,568	218,000	8,431	104.0%
売上原価 Cost of sales	98,027	100,975	2,948	103.0%	129,447	133,700	4,252	103.3%
売上総利益 Gross profit	61,491	65,078	3,587	105.8%	80,121	84,300	4,178	105.2%
運送費、保管料 Transportation and storage	5,895	6,298	402	106.8%	7,708	8,300	591	107.7%
広告宣伝費 Advertising	3,079	3,050	△ 29	99.1%	3,546	3,600	53	101.5%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	24,214	23,957	△ 256	98.9%	32,954	33,500	545	101.7%
研究開発費 Research and development	2,412	2,485	72	103.0%	3,376	3,800	423	112.5%
管理費、その他 Other, net	16,997	18,706	1,708	110.1%	23,044	25,300	2,255	109.8%
販売費及び一般管理費 SG&A expenses	52,599	54,497	1,897	103.6%	70,631	74,500	3,868	105.5%
宝酒造 グループ Takara Shuzo Group	7,041	8,435	1,393	119.8%	6,329	6,800	470	107.4%
タカラバイオ グループ Takara Bio Group	908	1,263	355	139.1%	1,954	＊ 2,000	46	102.4%
宝ヘルスケア Takara Healthcare Inc.	5	30	24	589.3%	21	30	8	139.6%
その他 Other, net	936	851	△ 84	91.0%	1,184	970	△ 214	81.9%
営業利益(△:損失) Operating income(Δ:loss)	8,891	10,580	1,689	119.0%	9,490	9,800	309	103.3%
受取利息・配当金 Interest and Dividends income	469	572	102	121.8%	562	600	37	106.7%
その他営業外収益 Other, net	332	385	52	115.8%	559	500	△ 59	89.3%
営業外収益 Non-operating income	802	957	155	119.3%	1,122	1,100	△ 22	98.0%
支払利息 Interest and discounts expenses	340	347	6	102.0%	464	600	135	129.2%
その他営業外費用 Other, net	147	220	73	150.0%	238	300	61	125.7%
営業外費用 Non-operating expenses	488	568	80	116.5%	703	900	196	128.0%
経常利益(△:損失) Ordinary income(Δ:loss)	9,205	10,969	1,764	119.2%	9,909	10,000	90	100.9%
特別利益 Extraordinary income	9,453	312	△ 9,141	3.3%	9,565	—	△ 9,565	—
特別損失 Extraordinary loss	262	529	267	202.1%	832	300	△ 532	36.0%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	18,397	10,752	△ 7,644	58.4%	18,642	9,700	△ 8,942	52.0%
法人税、住民税及び事業税 Current income taxes	7,151	3,578	△ 3,572	50.0%	7,140	3,700	△ 3,935	48.5%
法人税等調整額 Deferred income taxes	422	1,009	587	239.0%	495			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	10,823	6,163	△ 4,659	57.0%	11,006	6,000	△ 5,006	54.5%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	319	179	△ 139	56.3%	726	700	△ 26	96.4%
四半期純利益(△:損失) Net income(Δ:loss)	10,503	5,984	△ 4,519	57.0%	10,280	5,300	△ 4,980	51.6%
設備投資額(有形・無形) Capital expenditures	5,324	6,529	1,204	122.6%	8,967	10,337	1,370	115.3%
減価償却費(有形・無形) Depreciation and Amortization	3,111	2,962	△ 149	95.2%	4,287	4,300	12	100.3%

＊ タカラバイオグループは、平成27年3月期通期業績予想を、1/30に修正しております。(p3参照)
Takara Bio Group revised FY2015 forecasts on January 30, 2015. (c.f. p3.)

営業外収益 Non-operating income	受取利息157、受取配当金414、持分法による投資利益160 など Interest income 157, Dividends income 414, Equity in earnings of affiliates 160, etc.
営業外費用 Non-operating expenses	支払利息132、社債利息215 など Interest expense 132, Interest on bonds 215, etc.
特別利益 Extraordinary income	投資有価証券売却益249 など (前期:関係会社株式売却益9,261 など) Gain on sales of investment securities 249, etc.(FY2014(1Q-3Q):Gain on sales of subsidiaries and affiliates' stocks 9,261, etc.)
特別損失 Extraordinary loss	固定資産除売却損226、減損損失247 など Loss on sales and retirement of noncurrent assets 226, Impairment loss 247, etc.

2. 宝酒造グループ Takara Shuzo Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成26年3月期 第3四半期累計	平成27年3月期 第3四半期累計 Apr. 1, 2014 - Dec. 31, 2014			平成26年3月期 通期	平成27年3月期 通期 Apr. 1, 2014 - Mar. 31, 2015		
	実績(a) FY2014(1Q-3Q) Actual (a)	実績(b) FY2015(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2014 Actual (c)	11/5予想(d) FY2015 Forecast announced Nov. 2014 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
焼酎 Shochu	51,992	49,675	△ 2,316	95.5%	65,977	62,500	△ 3,477	94.7%
清酒 Sake	18,767	19,817	1,049	105.6%	23,510	26,300	2,789	111.9%
ソフトアルコール飲料 Light-alcohol refreshers	21,228	20,249	△ 978	95.4%	26,772	26,000	△ 772	97.1%
その他酒類 Other liquors	9,299	10,128	828	108.9%	12,585	12,500	△ 85	99.3%
本みりん Hon Mirin	11,655	11,368	△ 287	97.5%	14,886	14,300	△ 586	96.1%
その他調味料 Other seasonings	6,658	6,969	310	104.7%	8,645	9,000	354	104.1%
原料用アルコール等 Raw alcohol	5,065	5,378	313	106.2%	6,899	7,700	800	111.6%
海外日本食材卸 Japanese food wholesale business in overseas markets	6,039	12,747	6,708	211.1%	9,077	16,900	7,822	186.2%
その他 Other	10,143	9,843	△ 300	97.0%	13,950	14,100	149	101.1%
売上高 Net sales	140,850	146,178	5,327	103.8%	182,306	189,300	6,993	103.8%
売上原価 Cost of sales	89,404	91,977	2,573	102.9%	116,619	120,400	3,780	103.2%
売上総利益 Gross profit	51,446	54,200	2,754	105.4%	65,686	68,900	3,213	104.9%
運送費、保管料 Transportation and storage	5,424	5,758	334	106.2%	7,067	7,600	532	107.5%
広告宣伝費 Advertising	2,757	2,698	△ 59	97.9%	3,115	3,100	△ 15	99.5%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,422	23,258	△ 163	99.3%	31,889	32,500	610	101.9%
研究開発費 Research and development	250	250	△ 0	99.9%	341	400	58	117.1%
管理費、その他 Other, net	12,549	13,798	1,248	109.9%	16,943	18,500	1,556	109.2%
販売費及び一般管理費 SG&A expenses	44,404	45,764	1,360	103.1%	59,357	62,100	2,742	104.6%
営業利益(△:損失) Operating income(Δ:loss)	7,041	8,435	1,393	119.8%	6,329	6,800	470	107.4%
営業外収益 Non-operating income	350	434	83	123.9%	466	400	△ 66	85.7%
営業外費用 Non-operating expenses	179	287	107	160.1%	321	300	△ 21	93.2%
経常利益(△:損失) Ordinary income(Δ:loss)	7,213	8,583	1,369	119.0%	6,474	6,900	425	106.6%
特別利益 Extraordinary income	118	62	△ 56	52.7%	139	—	△ 139	—
特別損失 Extraordinary loss	225	236	11	105.1%	595	200	△ 395	33.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	7,106	8,409	1,302	118.3%	6,018	6,700	681	111.3%
法人税、住民税及び事業税 Current income taxes	2,741	2,741	0	100.0%	2,636	2,650	△ 126	95.4%
法人税等調整額 Deferred income taxes	156	216	60	138.8%	140			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	4,209	5,450	1,241	129.5%	3,241	4,050	808	124.9%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	136	233	96	170.6%	188	200	11	105.9%
四半期純利益(△:損失) Net income(Δ:loss)	4,072	5,217	1,144	128.1%	3,052	3,850	797	126.1%
設備投資額(有形・無形) Capital expenditures	1,969	3,461	1,491	175.7%	2,954	5,125	2,170	173.5%
減価償却費(有形・無形) Depreciation and Amortization	2,143	2,293	150	107.0%	2,968	2,900	△ 68	97.7%

*平成26年3月期の実績において、「清酒」の一部を「その他酒類」に、「その他」の一部を「海外日本食材卸」に、それぞれ組替えております。
(平成27年3月期の区分に合わせております。)

3. タカラバイオグループ Takara Bio Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成26年3月期 第3四半期累計	平成27年3月期 第3四半期累計 Apr. 1, 2014 - Dec. 31, 2014			平成26年3月期 通期	平成27年3月期 通期 Apr. 1, 2014 - Mar. 31, 2015		
	実績(a) FY2014(1Q-3Q) Actual (a)	実績(b) FY2015(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2014 Actual (c)	1/30予想(d) FY2015 Forecast announced Jan. 2015 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
研究用試薬 Research reagents	11,008	12,021	1,012	109.2%	15,761	17,535	1,773	111.3%
理化学機器 Scientific instruments	1,634	1,700	65	104.0%	2,686	2,449	△ 236	91.2%
受託・その他 Contracted service and other	1,878	1,775	△ 102	94.5%	3,215	3,485	270	108.4%
バイオ産業支援 計 Bioindustry	14,521	15,497	975	106.7%	21,663	23,470	1,807	108.3%
遺伝子医療 Gene Therapy	—	—	—	—	—	—	—	—
医食品バイオ AgriBio	1,645	1,796	150	109.1%	2,242	2,429	186	108.3%
売上高 Net sales	16,167	17,293	1,126	107.0%	23,905	25,900	1,994	108.3%
売上原価 Cost of sales	7,500	7,839	339	104.5%	11,331	12,060	729	106.4%
売上総利益 Gross profit	8,666	9,453	786	109.1%	12,574	13,839	1,265	110.1%
運送費、保管料 Transportation and storage	393	453	60	115.3%	537	611	74	113.8%
広告宣伝費 Advertising	94	84	△ 10	89.1%	121	121	△ 0	100.0%
販売促進費 Sales promotion	732	634	△ 97	86.7%	985	884	△ 100	89.8%
研究開発費 Research and development	2,154	2,225	70	103.3%	3,026	3,502	475	115.7%
管理費、その他 Other, net	4,383	4,792	408	109.3%	5,949	6,518	569	109.6%
販売費及び一般管理費 SG&A expenses	7,758	8,190	431	105.6%	10,619	11,638	1,018	109.6%
バイオ産業支援 Bioindustry	2,918	3,199	281	109.6%	4,806	5,070	263	105.5%
遺伝子医療 Gene Therapy	△ 628	△ 670	△ 42	—	△ 949	△ 1,145	△ 196	—
医食品バイオ AgriBio	△ 165	△ 147	17	—	△ 285	△ 208	77	—
共通 Eliminations/Corporate	△ 1,216	△ 1,118	98	—	△ 1,617	△ 1,515	101	—
営業利益(△:損失) Operating income(Δ:loss)	908	1,263	355	139.1%	1,954	2,200	246	112.6%
営業外収益 Non-operating income	164	158	△ 6	96.0%	372	516	143	138.4%
営業外費用 Non-operating expenses	81	37	△ 43	46.0%	86	56	△ 30	64.6%
経常利益(△:損失) Ordinary income(Δ:loss)	991	1,384	392	139.6%	2,240	2,660	420	118.8%
特別利益 Extraordinary income	0	—	△ 0	—	0	0	0	189.3%
特別損失 Extraordinary loss	34	273	239	795.5%	55	283	228	514.8%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	957	1,110	152	116.0%	2,185	2,377	192	108.8%
法人税、住民税及び事業税 Current income taxes	545	726	181	133.2%	756	1,375	648	189.3%
法人税等調整額 Deferred income taxes	△ 125	479	604	—	△ 30			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	537	△ 95	△ 632	—	1,458	1,002	△ 456	68.7%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 5	△ 10	△ 5	—	△ 11	1	13	—
四半期純利益(△:損失) Net income(Δ:loss)	542	△ 84	△ 627	—	1,470	1,000	△ 469	68.0%
設備投資額(有形・無形) Capital expenditures	3,230	3,008	△ 222	93.1%	5,538	4,444	△ 1,093	80.3%
減価償却費(有形・無形) Depreciation and Amortization	849	560	△ 288	66.0%	1,157	1,340	183	115.8%

*平成26年3月期通期実績の売上高およびセグメント別損益(営業利益)は、平成26年4月1日付の組織改正に従って、監査実施後の確定数値に組み替えて表示しております。

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	前期対比 Change from FY2014(1Q-3Q) 増減 Change	前期対比 Change from FY2014(1Q-3Q) 比 YOY%
売上高	Net sales	147,932	147,969	153,915	155,025	159,519	166,054	6,535	104.1%
売上原価	Cost of sales	89,345	89,423	93,282	94,618	98,027	100,975	2,948	103.0%
（売上高原価率）	(Ratio to Net sales)	60.4%	60.4%	60.6%	61.0%	61.5%	60.8%	-0.6pt	—
売上総利益	Gross profit	58,587	58,545	60,633	60,407	61,491	65,078	3,587	105.8%
販売費及び一般管理費	SG&A expenses	49,333	49,271	50,907	51,246	52,599	54,497	1,897	103.6%
（売上高販管費率）	(Ratio to Net sales)	33.3%	33.3%	33.1%	33.1%	33.0%	32.8%	-0.2pt	—
営業利益（△：損失）	Operating income(Δ:loss)	9,253	9,274	9,725	9,160	8,891	10,580	1,689	119.0%
（売上高営業利益率）	(Ratio to Net Sales)	6.3%	6.3%	6.3%	5.9%	5.6%	6.4%	+0.8pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	22,544	22,768	23,723	24,283	24,214	23,957	Δ 256	98.9%
（売上高販促費率）	(Ratio to Net sales)	15.2%	15.4%	15.4%	15.7%	15.2%	14.4%	-0.8pt	—
研究開発費	R&D expenses	2,525	2,103	2,169	2,264	2,412	2,485	72	103.0%
（売上高研究開発費率）	(Ratio to Net sales)	1.7%	1.4%	1.4%	1.5%	1.5%	1.5%	-0.0pt	—
設備投資額（有形・無形）	Capital expenditures	2,617	2,422	3,694	4,102	5,324	6,529	1,204	122.6%
減価償却費（有形・無形）	Depreciation and Amortization	3,589	3,352	3,284	3,132	3,111	2,962	Δ 149	95.2%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	前期対比 Change from FY2014(1Q-3Q) 増減 Change	前期対比 Change from FY2014(1Q-3Q) 比 YOY%
売上高	Net sales	130,996	131,604	137,671	138,367	140,850	146,178	5,327	103.8%
売上原価	Cost of sales	80,973	81,436	85,802	86,994	89,404	91,977	2,573	102.9%
（売上高原価率）	(Ratio to Net sales)	61.8%	61.9%	62.3%	62.9%	63.5%	62.9%	-0.6pt	—
売上総利益	Gross profit	50,023	50,168	51,868	51,372	51,446	54,200	2,754	105.4%
販売費及び一般管理費	SG&A expenses	41,871	42,038	43,813	43,789	44,404	45,764	1,360	103.1%
（売上高販管費率）	(Ratio to Net sales)	32.0%	31.9%	31.8%	31.6%	31.5%	31.3%	-0.2pt	—
営業利益（△：損失）	Operating income(Δ:loss)	8,151	8,129	8,055	7,582	7,041	8,435	1,393	119.8%
（売上高営業利益率）	(Ratio to Net sales)	6.2%	6.2%	5.9%	5.5%	5.0%	5.8%	+0.8pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	21,688	21,988	22,986	23,542	23,422	23,258	Δ 163	99.3%
（売上高販促費率）	(Ratio to Net sales)	16.6%	16.7%	16.7%	17.0%	16.6%	15.9%	-0.7pt	—
設備投資額（有形・無形）	Capital expenditures	1,797	1,634	1,647	1,735	1,969	3,461	1,491	175.7%
減価償却費（有形・無形）	Depreciation and Amortization	2,553	2,402	2,369	2,205	2,143	2,293	150	107.0%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	前期対比 Change from FY2014(1Q-3Q) 増減 Change	前期対比 Change from FY2014(1Q-3Q) 比 YOY%
売上高	Net sales	13,563	13,035	13,443	13,916	16,167	17,293	1,126	107.0%
売上原価	Cost of sales	6,387	6,090	6,066	6,275	7,500	7,839	339	104.5%
（売上高原価率）	(Ratio to Net sales)	47.1%	46.7%	45.1%	45.1%	46.4%	45.3%	-1.1pt	—
売上総利益	Gross profit	7,176	6,945	7,376	7,640	8,666	9,453	786	109.1%
販売費及び一般管理費	SG&A expenses	6,891	6,410	6,503	6,932	7,758	8,190	431	105.6%
（売上高販管費率）	(Ratio to Net sales)	50.8%	49.2%	48.4%	49.8%	48.0%	47.4%	-0.6pt	—
営業利益（△：損失）	Operating income(Δ:loss)	284	535	872	707	908	1,263	355	139.1%
（売上高営業利益率）	(Ratio to Net sales)	2.1%	4.1%	6.5%	5.1%	5.6%	7.3%	+1.7pt	—
研究開発費	R&D expenses	2,252	1,819	1,896	1,993	2,154	2,225	70	103.3%
（売上高研究開発費率）	(Ratio to Net sales)	16.6%	14.0%	14.1%	14.3%	13.3%	12.9%	-0.5pt	—
設備投資額（有形・無形）	Capital expenditures	728	721	589	2,058	3,230	3,008	Δ 222	93.1%
減価償却費（有形・無形）	Depreciation and Amortization	928	841	811	817	849	560	Δ 288	66.0%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	前期対比 Change from FY2014(1Q-3Q) 増減 Change	前期対比 Change from FY2014(1Q-3Q) 比 YOY%
売上高	Net sales	2,041	2,052	1,910	1,612	1,027	1,230	203	119.8%
売上原価	Cost of sales	1,482	1,404	1,240	1,013	475	597	121	125.6%
（売上高原価率）	(Ratio to Net sales)	72.6%	68.4%	65.0%	62.9%	46.3%	48.6%	+2.3pt	—
売上総利益	Gross profit	558	647	669	598	551	632	81	114.7%
販売費及び一般管理費	SG&A expenses	775	832	756	621	546	602	56	110.3%
（売上高販管費率）	(Ratio to Net sales)	38.0%	40.5%	39.6%	38.6%	53.2%	49.0%	-4.2pt	—
営業利益（△：損失）	Operating income(Δ:loss)	Δ 216	Δ 184	Δ 87	Δ 22	5	30	24	589.3%
（売上高営業利益率）	(Ratio to Net sales)	—	—	—	—	0.5%	2.4%	+1.9pt	—
ヘルスケア事業売上高	Net sales of Healthcare products	576	796	948	931	1,027	1,230	203	119.8%
設備投資額（有形・無形）	Capital expenditures	—	—	31	1	2	2	0	135.7%
減価償却費（有形・無形）	Depreciation and Amortization	7	7	8	8	0	1	0	520.6%